touchIMMUNOLOGY caught up with Professor Jean-Frederic Colombel (The Mount Sinai Hospital, NY, USA) to discuss the results from the UPA phase 3 programme, investigating the efficacy of upadacitinib on  the extraintestinal manifestations of ulcerative colitis.
The abstract entitled ‘Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC): Results from the UPA Phase 3 programme’ (Presentation no. OP33) was presented at the 17th Congress of ECCO, February 16-19, 2022!
Questions
- Could you tell us a little about the extraintestinal manifestations of ulcerative colitis (UC) and their impact on patient quality of life? (0:16)
- What have we learned from the U_ACHIEVE and U-ACCOMPLISH studies on the efficacy and safety of upadacitinib in patients with moderate-to-severe UC and what were the findings from the analysis you are presenting? (1:10)
- What will be the clinical impact of these findings? (3:09)
- Where do you see upadacitinib fitting in the treatment paradigm for UC? (4:03)
Disclosures: Jean-Frederic Colombel reports receiving research grants, payment for lectures and consulting fees from AbbVie.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ECCO-IBD virtual 2022.
